Skip to Content

FDA Approves Re-Formulated Clarinex Reditabs

KENILWORTH, N.J., July 15, 2005 -- Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved re-formulated Clarinex (desloratadine 2.5 mg and 5 mg) Reditabs tablets for the treatment of allergy symptoms caused by both perennial indoor and seasonal outdoor allergens and chronic idiopathic urticaria (CIU), or hives of unknown cause, in adults and children 6 years of age and older. The tablet disintegrates orally, is taken once-daily for 24-hour relief, and now comes in a new "tutti frutti" flavor. This convenient new formulation will be available in both a 2.5 mg and a 5 mg dose, and will be in pharmacies nationwide in September 2005.

"The Clarinex Reditabs formulation offers my patients a new, convenient treatment option for their allergies," said William Berger, M.D., a clinical professor in the Division of Allergy and Immunology at the University of California, Irvine. "An orally disintegrating tablet allows my patients the convenience to take their medication anytime and wherever they are even without water, and the once-daily dose helps them start each day with their symptoms under control."

The tablet dissolves rapidly allowing allergy sufferers to take their medication when it is convenient for them, even when they do not have access to water. Patients who have active lifestyles or dislike swallowing pills may prefer Reditabs for their allergy treatment. Options like Reditabs, make it possible to identify the most appropriate allergy treatment for each patient given their lifestyle and preferences.

"This new formulation, along with the currently available Clarinex family of products, helps physicians tailor the treatment regimen to patients’ specific needs and allows them to provide a variety of safe and effective allergy treatments for both children and adults," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough.

Clarinex is the only prescription nonsedating antihistamine approved for patients as young as 6 months old and is available in different forms to accommodate patient preference and symptoms. The Clarinex family of products includes Clarinex (0.5 mg per 1 mL) Syrup for children as young as 6 months old, Clarinex Reditabs for both adults and children starting at 6 years of age and Clarinex (5 mg) Tablets and Clarinex-D 24 Hour (desloratadine 5 mg/pseudoephedrine 240 mg) Extended Release Tablets for patients 12 years of age and older. Clarinex-D 24 Hour combines an antihistamine with a decongestant for patients suffering from nasal congestion associated with seasonal allergic rhinitis.

Source: Schering-Plough Corporation

Posted: July 2005